Elastic fibers and amyloid deposition in vascular tissue

Future Neurology

Volumn 2, Issue 5, 2007, Pages 523-536

  Bochicchio, Brigida ^a   Pepe, Antonietta ^a   Tamburro, Antonio M ^a  

^a UNIVERSITY OF BASILICATA   (Italy)

Author keywords

Amyloid structure; Amyloids; Cardiovascular amyloids; Mechanism

Indexed keywords

AMYLOID; ANTIOXIDANT; CATECHIN; CURCUMIN; ELASTIN; GAMMA SECRETASE INHIBITOR; GINKGO BILOBA EXTRACT; LITHIUM SALT; MELATONIN; NONSTEROID ANTIINFLAMMATORY AGENT; PHENOLSULFONPHTHALEIN; POLYPEPTIDE; POLYPHENOL DERIVATIVE; RESVERATROL;

AGING; ALZHEIMER DISEASE; AORTA INTIMA; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DEGENERATIVE DISEASE; DEMENTIA; DRUG MECHANISM; ELASTIC FIBER; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN STRUCTURE; QUALITY OF LIFE; REVIEW; VASCULAR TISSUE;

EID: 34648822550     PISSN: 14796708     EISSN: None     Source Type: Journal    
DOI: 10.2217/14796708.2.5.523     Document Type: Review

References (119)

1. Pear BL: Other organs and other amyloids. Semin. Roentgenol. 21(2), 150-161 (1986).
2. Eklund L: Radiologic findings in renal amyloidosis. Am. J. Roetgenol. 129(5), 851-853 (677).
3. Stefani M, Dobson CM: Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J. Mol. Med 81(11), 678-699 (2003).
4. Merlini G, Bellotti V: Molecular mechanisms of amyloidosis. N. Engl. J. Med. 349(6), 583-596 (2003).
5. Selkoe DJ: Translating cell biology into therapeutic advance in Alzheimer's disease. Nature 399(6738 Suppl.), A23-A31 (1999).
6. Glenner GG, Wong CW: Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120, 885-890 (1984).
7. Lee VM, Goedert M, Trojanowski JQ: Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24, 1121-1159 (2001).
8. Dumoulin M, Dobson CM: Probing the origins, diagnosis and treatment of amyloid diseases using and antibodies. Biochimie 86(9-10), 589-600 (2004).
9. Honig L-S, Kukull W, Mayeux R: Atherosclerosis and AD: analysis of data from the US National Alzheimer's Coordinating Center. Neurology 64(3), 494-500 (2005).
10. Howlett GJ, Moore KJ: Untangling the role of amyloid in atherosclerosis. Curr. Opin. Lipidol. 17(5), 541-7547 (2006).
11. Hirsch-Reinshagen V, Maia LF, Burgess BL et al.: The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease. J. Biol. Chem. 280(52), 43243-43256 (2005).
12. Koldamova R. Staufenbiel M, Lefterov I: Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice. J. Biol. Chem. 280(52), 43224-43235 (2005).
13. Galzitskaya OV, Garbuzynskiy SO, Lobanov MY: Is it possible to predict amyloidogenic regions from sequence alone? J. Bioinform. Comput. Biol. 4(2), 373-388 (2006).
14. Cornett J, Smith L, Friedman M, Shin JY, Li XJ, Li SH: Convext-dependent dysregulation of transcription by mutant huntingtin. J. Biol Chem. 281(47), 36198-36204 (2006).
15. Steiner I, Hajkova P: Patterns of isolated atrial amyloid: a study of 100 hearts on autopsy. Cardiovasc. Pathol. 15(5), 287-290 (2006).
16. Cornwell GG 3rd, Johnson KH, Westermark P: The age related amyloids: a growing family of unique biochemical substances. J. Clin. Pathol. 48(11), 984-989 (1995).
17. Johansson B, Westermark P: The relation of atrial natriuretic factor to isolated atrial amyloid. Exp. Mol. Pathol. 52(3), 266-278 (1990).
18. Goffin YA, Rickaert F: Histopographic evidence that amyloid deposits in sclerocalcific heart valves and other chronic lesions of the cardiovascular system are related to old thrombotic material. Virchows Arch. A Pathol. Anat. Histopathol. 409(1), 61-77 (1986).
19. Rocken C, Tautenhahn J, Buhling F et al.: Prevalence and pathology of amyloid in atherosclerotic arteries. Arterioscler. Thromb. Vasc. Biol. 26(3), 676-677 (2006).
20. Tassabehji M, Metcalfe K, Hurst J et al: An elastin gene mutation producing abnormal tropoelastin and abnormal elastic fibres in a patient with autosomal dominant cutis laxa. Hum. Mol. Genet. 7(6), 1021-1028 (1998).
21. Zhang MC, He L, Giro M, Yong SL, Tiller GF, Davidson JM: Cutis laxa arising from frameshift mutations in exon 30 of the elastin gene (ELN). J. Biol. Chem. 274(2), 981-986 (1999).
22. Tassabehji M, Urban Z: Congenital heart disease:.molecular diagnostics of supravalvular aortic stenosis. Methods Mol. Med. 126, 129-156 (2006).
23. Pasquali Ronchetti I, Alessandrini A, Baccarani Contri M et al.: Study of elastic fiber organization by scanning force microscopy. Matrix Biol. 17(1), 75-83 (1998).
24. Pepe A, Guerra D, Bochicchio B et al.: Dissection of human tropoelastin: supramolecular organization of polypeptide sequences coded by particular exons. Matrix Biol. 24(2), 96-109 (2005).
25. Tamburro AM, De Stradis A, D'Alessio L: Fractal aspects of elastin supramolecular orgnization. J. Biomol. Struct. Dyn. 12(6), 1161-1172 (1995).
26. Tamburro AM, Pepe A, Bochicchio B, Quaglino D, Ronchetti IP: Supramolecular amyloid-like assembly of the polypeptide sequence coded by exon 30 of human tropoelastin. J. Biol. Chem. 280(4), 2682-2690 (2005).
27. Mucchiano GI, Haqqvist B, Sletten K, Westermark P: Apolipoprotein A-1-derived amyloid in atherosclerotic plaques of the human aorta. J. Phathol. 193(2), 270-275 (2001).
28. Wisniewski HM, Wegiel J, Vorbrodt AW, Mazur-Kolecka B, Frackowiak J: Role of perivascular cells and myocytes m vascular amyloidosis. Ann. NY Acad. Sci. 903, 6-18 (2000).
29. Verbeek MM, Van Nostrand WE, Otte-Holler I, Wesseling P, De Waal RM: Amyloid-β-induced degeneration of human brain pericytes is dependent on the apolipoprotein E genotype. Ann. NY Acad. Sci. 903, 187-199 (2000).
30. Westermark P, Mucchiano G, Marthin T, Johnson KH, Sletten K: Apolipoprotein A1-derived amyloid in human aortic atherosclerotic plaques. Am. J. Pathol. 147(5), 1186-1192 (1995).
31. Amarzguioui M, Mucchiano G, Haggqvist B et al.: Extensive intimal apolipoprotein A1-derived amyloid deposits in a patient with an apolipoprotein A1 mutation. Biochem. Biophys. Res. Commun. 242(3), 534-539 (1998).
32. Larsson A, Peng S, Persson H et al.: Latadherin binds to elastin - a starting point for medin amyloid formation? Amyloid 13(2), 78-85 (2006).
33. Haggqvist B, Naslund J, Sletten K et al.: Medin: an integral fragment of aortic smooth muscle cell-produced lactadherin forms the most common human amyloid. Proc. Natl Acad. Sci. USA 96(15), 8669-8674 (1999).
34. Kiuru-Enari S, Keski-Oja J, Haltia M: Cutis laxa in hereditary gelsolin amyloidosis. Br. J. Dermatol. 152(2), 250-257 (2005).
35. Kozel BA, Wachi H, Davis EC, Mecham RP: Domaim in tropoelastin that mediate elastin deposition in vitro and in vivo. J. Biol. Chem. 278(20), 18491-18498 (2003).
36. Miao M, Bellingham CM, Stahl RJ, Sitarz EE, Lane CJ, Keeley FW: Sequence and structure determinants for the self-aggregation of recombinant polypeptides modeled after human elastin. J. Biol. Chem. 278(49), 48553-48562 (2003).
37. Bellingham CM, Woodhouse KA, Robson P, Rothstein SJ, Keeley FW: Self-aggregation characteristics of recombinantly expressed human elastin polypeptides. Biochim. Biophys. Acta 1550(1), 6-19 (2001).
38. Jimenez JL, Nettleton EJ, Bouchard M, Robinson CV, Dobson CM, Saibil HR: The protofilament: structure of insulin amyloid fibrils. Proc. Natl Acad Sci. USA 99(14), 9196-9201 (2002).
39. Fan K. Nagle WA: Amyloid associated with elastin-staining laminar aggregates in the lungs of patients diagnosed with acute respiratory distress syndrome. BMC Pulm. Med. 2, 5 (2002).
40. Guantieri V, Tamburro AM, Gordini DD: Interactions of human and bovine elastins with lipids: their proteolysis by elastase. Connect. Tissue Res. 12(1), 79-83 (1983).
41. Claire M, Jacotot B, Robert L: Characterization of lipids associated with macromolecules of the intercellular matrix of human aorta. Connect. Tissue Res. 4(2), 61-71 (1976).
42. Dobson CM: Protein misfolding, evolution and disease. Trends Biochem Sci. 24(9), 329-332 (1999).
43. Dobson CM: The structural basis of protein folding and its links with human disease. Philos. Trans. Soc. Lond. B, Biol. Sci. 356(1406), 133-145 (2001).
44. Rauscher S, Baud S, Miao M, Keeley FW, Pomes R: Proline and glycine control protein self-organization into elastomeric or amyloid fibrils. Structure 14(11), 1667-1676 (2006).
45. Gasser M, Baldwin MA, Lloyd DH et al.: Predicted α-helical regions of the prion protein when synthesized as peptides form amyloid. Proc. Natl Acad. Sci. USA 89(22), 10940-10944 (1992).
46. Ostuni A, Bochicchio B, Armentano MF, Bisaccia F, Tamburro AM, Molecular and supramolecular structural studies on human tropoelastin sequences. Biophys. J. (2007) (In press).
47. Flamia R, Zhdan PA, Martino M, Castle JE, Tamburro AM: AFM study of the elastin-like biopolymer poly(ValGlyGlyValGly). Biomacromolecules 5(4), 1511-1518 (2004).
48. Bochicchio B, Floquet N, Pepe A. Alix AJ, Tamburro AM: Dissection of human tropoelastin: solution structure, dynamics and self-assembly of the exon 5 peptide. Chem. Eur. J. 10(13), 3166-3176 (2004).
49. Tamburro AM, Pepe A, Bochicchio, B: Localizing α-helices in human tropoelastin: assembly of the elastin 'puzzle'. Biochemistry 45(31), 9518-9530 (2006).
50. Tamburro AM, Bochicchio B, Pepe A: Dissection of human tropoelastin: exon-by-exon chemical synthesis and related conformational studies. Biochemistry 42(45), 13347-13362 (2003).
51. Jimenez JL, Guijarro JI, Orlova E et al.: Cryo-electron microscopy structure of an SH3 amyloid fibril and model of the molecular packing. EMBO J. 18(4), 815-821 (1999).
52. Fraser PE, Nguyen JT, Surcwicz WK, Kirschner DA: pH-dependent structural transitions of Alzheimer amyloid peptides. Biophys. J. 60(5), 1190-1201 (1991).
53. Bauer HH, Aebi U, Haner M, Hermann R, Muller M, Merkle HP: Architecture and polymorphism of fibrillar supramolecular assemblies produced by in vitro aggregation of human calcitonin. J. Struct. Biol. 115(1), 1-15 (1995).
54. Goldsbury CS, Cooper GJ, Goldie KN et al.: Polymorphic fibrillar assembly of human amylin. J. Struct. Biol. 119(1), 17-27 (1997).
55. Bouchard M, Zurdo J, Nettleton EJ, Dobson CM, Robinson CV: Formation of insulin amyloid fibrils followed by FTIR simultaneously with CD and electron microscopy. Protein Sci. 9(10), 1960-1967 (2000).
56. Cohen AS, Shirahama T, Skinner M: Electron microscopy of amyloid. In: Electron Microscopy of Proteins (Vol. 3). Harris JR (Ed.). Academic Press, London, UK 165-205 (1982).
57. Eanes ED, Glenner GG: X-ray diffraction studies on amyloid filaments. J. Histochem. Cytochem. 16(11), 673-677 (1968).
58. Sunde M, Serpell LC, Bartlam M, Fraser PE, Pepys MB, Blake CC: Common core structure of amyloid fibrils by synchrotron x-ray diffraction. J. Mol. Biol. 273(3), 729-739 (1997).
59. Blake C, Serpell L: Synchrotron x-ray studies suggest that the core of the transthyretin amyloid fibril is a continuous β-sheet helix. Structure 4(8), 989-998 (1996).
60. Burke MJ, Rougvie MA: Cross-protein structures. I. Insulin fibrils. Biochemistry 11(13), 2435-2439 (1972).
61. Tycko R: Progress towards a molecular-level structural understanding of amyloid fibrils. Curr. Opin. Struct. Biol. 14(1), 96-103 (2004).
62. Nelson R, Sawaya MR, Balbirnie M et al.: Structure of the cross-β spine of amyloid-like fibrils. Nature 435(7043), 773-778 (2005).
63. Lansbury PT Jr, Costa PR, Griffiths JM et al.: Structural model fbr the β-amyloid fibril based on interstrand alignment of an antiparallel-sheet comprising a C-terminal peptide. Nat. Struct. Biol. 2(11), 990-998 (1995).
64. Petkova AT, Baldus M, Belenky M, Hong M, Griffin RG, Herzfeld J: Backbone and side chain assignment strategies for multiply labeled membrane peptides and proteins in the solid state. J. Magn. Reson. 160(1), 1-12 (2003).
65. Cooper JH: Selective amyloid staining as a function of amyloid composition and structure. Histochemical analysis of the alkaline Congo fed, standardized toluidine blue, and iodine methods. Lab. Invest. 31(3), 232-238 (1974).
66. Glenner GG: Amyloid deposits and amyloidosis. The β-fibrilloses (first of two parts). N. Engl. J. Med. 302(23), 1283-1292 (1980).
67. Hollosi M, Otvos L Jr, Kajtar J, Percel A, Lee VM: Is amyloid deposition in Alzheimer's disease preceded by an environment-induced double conformational transition? Pept. Res. 2(1), 109-113 (1989).
68. Janek K, Rothemund S, Gast K et al.: Study of the conformational transition of Aβ(1-42) using D-amino acid replacement analogues. Biochemistry 40(18), 5457-5463 (2001).
69. Tomaselli S, Esposito V, Vangone P et al.: The α-to-β conformational trinsition of Alzheimer's; Aβ-(1-42) peptide in aqueous media is reversible- a step by step conformational analysis suggests the location of β conformation seeding. Chembiochem 7(2),257-267 (2006).
70. Koga T, Higuchi M, Kinoshita T, Higashi N: Controlled self-assembly of amphiphilic oligopeptides into shape-specific nanoarchitectures. Chemistry 12(5), 1360-1367 (2006).
71. Mauro M, Craparo EF, Podesta A et al.: Kinetics of different processes in human insulin amyloid formation. J. Mol. Biol. 366(1), 258-274 (2007).
72. Dobson CM: Getting out of shape. Nature 418(6899), 729-130 (2002).
73. Aggeli A, Nyrkov IA, Bell M et al.: Hierarchical self-assembly of chiral rod-like molecules as a model for peptide β-sheet tapes, ribbons, fibrils, and fibers. Proc. Natl Acad Sci. USA 98(21), 11857-11862 (2001).
74. Rochet JC, Lansbury PT Jr: Amyloid fibrillogenesis: themes and variations. Curr. Opin. Struct. Biol. 10(1), 60-68 (2000).
75. Bochicchio B, Tamburro AM: Polyproline II structure in proteins: identification by chiroptical spectroscopies, stability, and functions. Chirality 14(10), 782-792 (2002).
76. Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury PT Jr: Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. USA 97(2), 571-576 (2000).
77. Yong W, Lomakin A, Kirkitadze MD, Teplow DB, Chen SH, Benedek GB: Structure determination of micelle-like intermediates in amyloid β-protein fibril assembly by using small angle neutron scattering. Proc. Natl Acad. Sci. USA 99(1), 150-154 (2002).
78. Lashuel HA, Hartley D, Petre BM, Walz T, Lansbury PT Jr: Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 418(6895), 291 (2002).
79. Lashuel HA, Petre BM, Wall J et al.: α-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J. Mol. Biol. 322(5), 1089-1102 (2002).
80. Zhang S, Marini DM, Hwang W, Santoso S: Design of nanostructured biological materials through self-assembly of peptides and proteins. Curr. Opin. Chem. Biol. 6(6), 865-871 (2002).
81. Mastrangelo IA, Ahmed M, Sato T et al.: High-resolution atomic force microscopy of soluble Aβ42 oligomers. J. Mol. Biol. 358(1), 106-119 (2006).
82. Ferrone FA, Hofrichter J, Eaton WA: Kinetics of sickle hemoglobin polymerization. II. A double nucleation mechanism. J. Mol. Biol. 183(4), 611-631 (1985).
83. Wetzel: Kinetics and thermodynamics of amyloid fibril assembly. Acc. Chem Res. 39(9),671-679 (2006).
84. Croixmarie V, Briki F, David G et al.: A cylinder-shaped double ribbon structure formed by an amyloid hairpin peptide derived from the β-sheet of murine PrP: an x-ray and molecular dynamics simulation study. J. Struct Biol. 150(3),284-299 (2005).
85. Lomakin A, Teplow DB, Kirschner DA, Benedek GB: Kinetic theory of fibrillogenesis of amyloid β-protein. Proc. Natl. Acad. Sci. USA 94(15), 7942-7947 (1997).
86. Perutz MF, Windle AH: Cause of neural death in neurodegenerative diseases attributable to expansion of glutamine repeats. Nature 412(6843), 143-144 (2001).
87. Gsponer J, Haberthur U, Caflisch A: The role of side-chain interactions in the early steps of aggregation: molecular dynamics simulations of an amyloid-forming peptide from the yeast prion Sup35. Proc. Natl Acad. Sci. USA 100(9), 5154-5159(2003).
88. Klimov, DK Thirumalai D: Dissecting the assembly of Aβ16-22 amyloid peptides into antiparallel β sheets. Structure 11(3), 295-307(2003).
89. Ma B, Nussinov R: Molecular dynamics simulations of alanine rich β-sheet oligomers: insight into amyloid formation. Protein Sci. 11(10), 2335-2350 (2002).
90. Gazit E: The 'correctly folded' state of proteins: is it a metastable state? Angew. Chem Int. Ed, Engl. 41(2), 257-259 (2002).
91. Meersman F, Dobson CM: Probing the pressure-temperature stability of amyloid fibrils provides new insights into their molecular properties. Biochim Biophys. Acta 1764(3), 452-460 (2006).,
92. Seilheimer B, Bohrmann B, Bondolfi L, Muller F, Stuber D, Dobeli H: The toxicity of the Alzheimer's β-amyloid peptide correlates with a distinct fiber morphology.J Struct. Biol. 119(1), 59-71 (1997).
93. Smeller L, Rubens P, Heremans K: Pressure effect on the temperature-induced unfolding and tendency to aggregate of myoglobin. Biochemistry 38(12), 3816-3820(1999).
94. Hwang W, Zhang S, Kamm RD, Karplus M: Kinetic control of dimer structure formation in amyloid fibrillogenesis. Proc Natl Acad. Sci. USA 101(35), 12916-12921 (2004).
95. Rochet JC; Novel therapeutic strategies for the treatment of protein-misfolding diseases. Expert Rev. Mol. Med. 9(17), 1-34 (2007).
96. Azriel R, Gazit E: Analysis of the minimal amyloid-forming fragment of the islet amyloid polypeptide. An experimental support for the key role of the phenylalanine residue in amyloid formation. J. Biol. Chem. 276(36), 34156-34161 (2001).
97. Tjernberg LO, Naslund J, Lindqvist F et al.: Arrest of β-amyloid fibril formation by a pentapeptide ligand. J. Biol. Chem. 271(15), 8545-8548 (1996).
98. Soto C, Kindy MS, Baumann M, Frangione B: Inhibition of Alzheimer's amyloidosis by peptides that prevent β-sheet conformation. Biochem Biophys. Res. Commun. 226(3), 672-680 (1996).
99. Gazit E: Mechanisms of amyloid fibril self-assembly and inhibition. Model short peptides as a key research tool. FEBS J. 272(23), 5971-5978 (2005).
100. Wang C, Huang L, Wang L, Hong Y, Sha Y: One-dimensional self-assembly of a rational designed β-structure peptide. Biapolymer 86(1), 23-31 (2007).
101. Wu C, Lei H, Wang Z, Zhang W, Duan Y: Phenol red interacts with the protofibril-like oligomers of an amyloidogenic herapeptide NFGAIL through both hydrophobic and aromatic contacts. Biophys. J. 91(10), 3664-3672 (2006).
102. Kim W, Kim Y, Min J, Kim DJ, Chang YT, Hecht MH: A high-throughput screen for compounds that inhibit aggregation of the Alzheimer's peptide. ACS Chem. Biol. 1(7), 461-469 (2006).
103. Chirita C, Necula M, Kuret J: Ligand-dependent inhibition and reversal of tau filament formation. Biochemistry 43(10), 2879-2887 (2004).
104. Wang J, Gines S, MacDonald ME, Gusella JF: Reversal of a full-length mutant huntingtin neuronal cell phenotype by chemical inhibitors of polyglutamine-mediated aggregation. BMC Neurosci. 6(1), 1 (2005).
105. Bertsch U, Winklhofer KF, Hirschberger T et al.: Systematic identification of antiprion drugs by high-throughput screening based on scanning for intensely fluoroscent targets. J. Virol. 79(12), 7785-7791 (2005).
106. De Jonghe C, Esselens C, Kumar-Singh S et al.: Pathogenic APP mutations near the γ-secretase cleavage site differentially affect Aβ secretion and APP C-terminal fragment stability. Hum. Mol. Genet. 10(16), 1665-1671 (2001).
107. Weggen S, Eriksen JL, Sagi SA et al.: Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid β 42 production by direct modulation of γ-secretase acitivity. J. Biol. Chem. 278(34), 31831-31837 (2003).
108. Best JD, Smith DW, Reilly MA et al.: The novel γ secrease inhibitor N-[cis-4-[(4-chlorophenl)sulfonyl]-4-(2,5-difluorophenyl) cyclohexyl]-1,1, 1-trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of notch-related pathology in the Tg2576 mouse. J. Pharmacol. Exp. Ther. 320(2), 552-558 (2007)
109. Chohan MO, Haque N, Alonso A et al.: Hyperphosphorylation-induced self assembly of murine tau: a comparison with human tau. J. Neural. Transm. 112(8), 1035-1047 (2005).
110. Tabner BJ, Turnbull S, King JE, Benson FE, El-Agnaf OM, Allsop D: A spectroscopic study of some of the peptidyl radicals formed following hydroxyl radical attack on β-amyloid and α-synuclein. Free Radic. Res. 40(7), 731-739 (2006).
111. Ono K, Yoshiike Y, Takashima A. Hasegawa K, Naiki H, Yamada M: Potent anti-amyloidogenic and fibrildestabilizing effects of polyphenols in vitro: implications tor the prevention and therapeutics of Alzheimer's disease. J. Neurochem. 87(1), 172-181 (2003).
112. Yang F, Lim GP, Begum AN et al.: Curcumin inhibits formation of amyloid β oligomers and fibrils, binds plaques, and reduce, amyloid in-vivo. J. Biol. Chem. 280(7), 5892-5901 (2005).
113. Han YS, Zheng WH, Bastianetto S, Chabot JG, Quirion R. Neuraprotective effects of resveratrol against β-amyloid-induced neurotoxicity in rat hippocampal neurons: involvement of Protein kinase C. Br. J. Pharmacol. 141(6), 997-1005 (2004).
114. Zhang YC, Wang ZF, Wang Q, Wang YP, Wang JZ: Melatonin attenuates β-amyloid-induced inhibition of neurofilament expression. Acta Pharmacol. Sin. 25(4), 447-451 (2004).
115. Pappolla M, Bozner P, Soto C et al.: Inhibition of Alzheimer β-fibrillogenesis by melatonin. J. Biol. Chem. 273(13), 7185-7188 (1998).
116. Chyan YJ, Poeggeler B, Omar RA et al.: Potent neuroprotective properties against the Alzheimer β-amyloid by an endogenous melatonin-related indole structure, indole-3-propionic acid. J. Biol. Chem. 274(31), 21937-21942 (1999).
117. Yao Z, Drieu K, Papadopoulos V: The Ginkgo biloba extract EGb 761 rescues the PC12 neuronal cells from β-amyloid-induced cell death by inhibiting the formation of β-amyloid-derived diffusible neurotoxic ligands. Brain Res. 889(1-2), 181-190 (2001).
118. Pratico D, Delanty N: Oxidative injury in diseases of the central nervous system: focus on Alzheimer's disease. Am J. Med. 109(7), 577-585 (2000).
119. Harris JR: In vitro fibrillogenesis of the amyloid β 1-42 peptide: cholesterol potentiation and aspirin inhibition. Micron 33(7-8), 609-626 (2002).